IGM Biosciences Inc

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IGM Biosciences reports progress in clinical development and strategic shifts

IGM Biosciences showcases progress in clinical development and financial performance.
Strategic shifts towards autoimmune indications present market opportunities.
Management addresses concerns and highlights safety profiles of key product candidates.
Potential for partnerships and differentiation in oncology and autoimmune diseases discussed.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STOCKHOLM , April 25, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Orphan Drugs Conference on April 27, 2022. CEO Jens Lindberg will present at 15.15 CET.

Medivir to present at the Redeye Orphan Drugs Conference

MOUNTAIN VIEW, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing on April 1, 2022 of its previously announced underwritten public offering of 8,695,653 shares of its non-voting common stock and, pursuant to the exercise in full by the underwriters of a 30-day option to purchase additional shares, 1,304,347 shares of its voting common stock, each at a price to the public of $23.00 per share. IGM received total gross proceeds of approximately $230.0 million from this offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by IGM. All of the shares in the offering were sold by IGM.

IGM Announces Closing of $230.0 Million Public Offering

Regeneron Pharmaceuticals

Sanofi

A week filled with promising announcements failed to jump-start Sanofi SA's ( SNY , Financial) shares, but it did for the two companies it's working with.

Regeneron, IGM Biosciences Shares Up Big on Sanofi Deals

Truist has lowered the price target on IGM Biosciences Inc (NASDAQ: IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA.

Why Did Truist Lower IGM Biosciences' Price Target?

MOUNTAIN VIEW, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its underwritten public offering of 8,695,653 shares of its non-voting common stock at a price to the public of $23.00 per share. IGM expects to receive total gross proceeds of approximately $200.0 million from this offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by IGM. In addition, IGM has granted the underwriters a 30-day option to purchase up to an additional 1,304,347 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering will be sold by IGM. The offering is expected to close on or about April 1, 2022, subject to satisfaction of customary closing conditions.

IGM Announces Pricing of $200.0 Million Public Offering

Allego NV

AMC Entertainment

FAT Brands

GameStop

PureCycle Technologies

The Valens Co

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.

8 Stocks Halted In Tuesday's Session

Here are the various catalysts investors in IGM Biosciences and IGMS stock are watching today as shares more than double. The post Why Is IGM Biosciences (IGMS) Stock Up Today?

Why Is IGM Biosciences (IGMS) Stock Up Today?

In addition to reporting its fourth-quarter results, the clinical-stage biotech announced a lucrative new collaboration deal with Sanofi.

Why IGM Biosciences Stock Rocketed Higher Today

Nielsen Hlds

Upward momentum on Wall Street continued.

These 2 Stocks Are Up 20%-Plus in Tuesday's Premarket

MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an underwritten public offering. In addition, IGM intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares at the public offering price, less underwriting discounts and commissions. All of the securities offered in the offering will be sold by IGM. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

IGM Announces Proposed Public Offering

– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate Development, Regulatory and Commercial Milestones –

IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast today, Tuesday, March 29, 2022, at 8:00 am ET to discuss the Company's global collaboration agreement with Sanofi, as recently announced.

IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement with Sanofi

Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets

Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets

IGMS develops IgM antibodies targeting cancer. The science is neat, however, trial results published at the last two ASH conferences didn't impress investors.

IGM Biosciences: Interesting Science, Poor Trial Data

IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent infection COVID-19.  Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Did IGM Biosciences Shares Advance Today?

– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested –

IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19

MOUNTAIN VIEW, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the Guggenheim 2022 Oncology Conference on Thursday, February 10, 2022 at 1:00 p.m. EST.

IGM Biosciences to Present at the Guggenheim 2022 Oncology Conference

IGM Biosciences, Inc. (IGMS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why IGM Biosciences, Inc. (IGMS) is Poised for a Turnaround After Losing 50.6% in 4 Weeks

MOUNTAIN VIEW, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 10:30 a.m. EST.

IGM Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

- Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and FL, and has a Favorable Safety Profile -

IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting

– Grant Agreement with the Bill & Melinda Gates Foundation Aims to Leverage IGM's Engineered IgM and IgA Antibodies to Address a Significant Driver of Morbidity and Mortality in Low- and Middle-Income Countries –

IGM Biosciences to Collaborate on the Study of IgM and IgA Antibodies for the Prevention of Malaria

MOUNTAIN VIEW, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 11, 2021, at 7:30 p.m. EST. The event will take place following an oral presentation featuring clinical data from the Phase 1 dose escalation study evaluating IGM-2323, the Company's novel CD20 x CD3 T cell engager IgM antibody for the treatment of B cell proliferative diseases, at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 63rd Annual ASH Meeting

MOUNTAIN VIEW, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 1:40 p.m. GMT/ 8:40 a.m. EST.

IGM Biosciences to Present at the Jefferies London Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 2:00 p.m. EST.

IGM Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference

– Plans to Initiate Phase 2 Studies of IGM-2323 in Diffuse Large B-cell Lymphoma and Follicular Lymphoma –

News for IGM Biosciences Inc Stock (IGMS)